

IN THE CLAIMS

Please amend the claims as follows:

1. (currently amended) A process for preparing a gabapentin tannate pharmaceutical composition ~~for treating a condition of the central nervous system in a mammalian subject~~, comprising: reacting gabapentin with tannic acid to produce a pharmaceutically effective amount of gabapentin tannate in solid dosage form wherein the tannic acid component is of either natural or synthetic origin.
2. (original) The process of claim 1 including selecting either natural or synthetic tannic acid.
3. (original) The process of claim 1 including providing one or more pharmaceutically acceptable excipients.
4. (currently amended) A process for preparing a gabapentin tannate pharmaceutical composition ~~for treating a condition of the central nervous system in a mammalian subject~~, comprising:
 - mixing an anti-clumping agent and tannic acid together to form a reaction mixture;
 - adding gabapentin to said reaction mixture; and
 - adding one or more solvents to said reaction mixture.
5. (original) The process of claim 4, including selecting said solvent from a group consisting of water, purified water, isopropyl alcohol, ethanol, glycerin, propylene glycol, mineral oil and mixtures thereof

6. (currently amended) A process for preparing a gabapentin tannate pharmaceutical composition ~~for treating a condition of the central nervous system in a mammalian subject~~, comprising:

mixing one or more anti-clumping agents, tannic acid and gabapentin together either in the presence of one or more solvents or at a suitable temperature so as to produce a pharmaceutically effective amount of gabapentin tannate.

7. (original) The process of claim 6, including selecting said solvents from a group consisting of water, purified water, ethanol, isopropyl alcohol, glycerin, propylene glycol, mineral oil and mixtures thereof.

8. (original) The process of claim 6, including providing said tannic acid at a weight W_1 and gabapentin at a weight W_2 wherein W_1 is from about 0.05 to about 20 times W_2 .

9. (original) The process of claim 8, including selecting said one or more anti-clumping agents from a group consisting of magnesium aluminum silicate, xanthan gum, polyvinylpyrrolidone, cellulose compounds, magnesium stearate, colloidal silica, talc, stearic acid, calcium stearate, lactose, mannitol, sucrose and mixtures thereof.

10. (original) The process of claim 9, including providing said one or more anti-clumping agents at a concentration of from about 0.01 to about 95% by weight of said composition.

11. (currently amended) A gabapentin tannate pharmaceutical composition ~~for treating a condition of the central nervous system in a mammalian subject~~, comprising as an active ingredient a pharmaceutically effective amount of gabapentin tannate in solid dosage form wherein the tannic acid component is of either natural or synthetic origin.

12. (original) The composition of claim 11 further including one or more pharmaceutical excipients.

13. (original) The composition of claim 12, wherein said excipients are selected from a group consisting of an anti-clumping agent, a filler, a diluent, a colorant, a sweetening agent, a lubricant, a binding agent, a disintegrating agent, a flavoring agent and mixtures thereof.

14. (original) The composition of claim 12, wherein said composition further includes one or more solvents selected from a group consisting of water, purified water, ethanol, isopropyl alcohol, glycerin, propylene glycol, mineral oil and mixtures thereof.

15. (original) The composition of claim 12, wherein said one or more excipients are sweetening agents selected from a group consisting of sucrose, saccharin sodium, aspartame, sucralose and mixtures thereof.

16. (original) The composition of claim 12, wherein said one or more excipients are anti-clumping agents selected from a group consisting of magnesium aluminum silicate, xanthan gum, polyvinylpyrrolidone, cellulose compounds, magnesium stearate, colloidal silica, talc, stearic acid, calcium stearate, lactose, mannitol, sucrose and mixtures thereof.

17. (currently amended) A method of treating a condition of the central nervous system in a mammalian subject wherein said condition of the central nervous system is selected from a group consisting of partial seizures, epilepsy, faintness attacks, hypokinesia, pain associated with shingles and cranial trauma, comprising administering a pharmaceutically effective amount of gabapentin tannate in solid dosage form.

18. (original) The method of claim 17 wherein said administering step is performed orally.

19. (original) The method of claim 17, including providing between about 0.1 to about 3600 mg of gabapentin in gabapentin tannate salt form.